<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749787</url>
  </required_header>
  <id_info>
    <org_study_id>PRTX-100-104</org_study_id>
    <nct_id>NCT01749787</nct_id>
  </id_info>
  <brief_title>Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis</brief_title>
  <acronym>SPARTA</acronym>
  <official_title>A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalex, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of PRTX-100 when
      various doses are given 5 times at weekly intervals to patients with active rheumatoid
      arthritis that are taking methotrexate or leflunomide. The drug is administered in a
      physician's office via an intravenous infusion. PRTX-100 may be effective in rheumatoid
      arthritis by suppressing the immune responses.

      PRTX-100 is a highly-purified bacterial protein called Staphylococcal Protein A. In this
      study, cohorts of patients with active RA will receive sequentially higher doses of PRTX-100.
      There will be an inactive placebo cohort for comparison. Patients who do not attain low RA
      disease activity, by a commonly used measure, will leave the study at 3 months after their
      first dose of study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Screening up to 53 Weeks</time_frame>
    <description>Number, severity and attribution of relatedness of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs and Physical Examinations</measure>
    <time_frame>Screening up to 25 Weeks</time_frame>
    <description>Change from baseline in blood pressure, heart rate, body temperature, and physical examination parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Screening, first dose, 5th dose, 9 weeks, and 25 weeks</time_frame>
    <description>Change from baseline in heart rate, PR interval, QT/QTc interval and QRS duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Testing</measure>
    <time_frame>Screening up to 25 weeks</time_frame>
    <description>Change from baseline in blood chemistry, hematology, and urinalysis values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>Screening up to 53 weeks</time_frame>
    <description>Number and percentage of patients attaining an ACR20, ACR50 and ACR70 response at Week 13. Change from baseline in CDAI, RAPID 3, and DAS28-CRP scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Prior to first dose, and at 4 weeks, 9 weeks, and 25 weeks</time_frame>
    <description>Proportion of patients sero-positive and/or with titers &gt; 512 at Week 4 and Week 9, the correlation between anti-product antibody and product clearance, and association between anti-product antibodies and adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Prior to first dose up to 72 hours after last dose of PRTX-100</time_frame>
    <description>Plasma Cmax, AUC0-n, clearance and Vd.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>1.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered via infusion once per week for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>420 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRTX-100 at 1.5 mcg/kg</intervention_name>
    <arm_group_label>1.5 mcg/kg</arm_group_label>
    <other_name>Staphylococcal Protein A</other_name>
    <other_name>SpA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRTX-100 at 3.0 mcg/kg</intervention_name>
    <arm_group_label>3.0 mcg/kg</arm_group_label>
    <other_name>Staphylococcal Protein A</other_name>
    <other_name>SpA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRTX-100 at 6.0 mcg/kg</intervention_name>
    <arm_group_label>6.0 mcg/kg</arm_group_label>
    <other_name>Staphylococcal Protein A</other_name>
    <other_name>SpA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRTX-100 at 12.0 mcg/kg</intervention_name>
    <arm_group_label>12.0 mcg/kg</arm_group_label>
    <other_name>Staphylococcal Protein A</other_name>
    <other_name>SpA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRTX-100 at 240 mcg</intervention_name>
    <arm_group_label>240 mcg</arm_group_label>
    <other_name>Staphylococcal Protein A</other_name>
    <other_name>SpA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered via infusion once per week for 5 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRTX-100 at 420 mcg</intervention_name>
    <arm_group_label>420 mcg</arm_group_label>
    <other_name>Staphylococcal Protein A</other_name>
    <other_name>SpA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active RA with disease duration of not less than 6 months

          -  Concomitant stable methotrexate or leflunomide therapy

        Exclusion Criteria:

          -  Diagnosis of any other inflammatory arthritis

          -  ACR Functional Classification of IV

          -  Significant systemic involvement secondary to RA (except for secondary Sjogren's
             syndrome)

          -  History of clincally significant hypogammaglobulinemia, common variable
             immunodeficiency, or humeral immunodeficientncy

          -  History of active tuberculosis, pro-thrombotic disorder, venous thrombosis requiring
             anti-coagulation, substance abuse, or serious psychiatric condition

          -  History of allergy or hypersensitivity to aspirin or non-steroidal cyclooxygenase
             inhibitors, Staphylococcal protein A

          -  History or presence of malignancy (except for surgically treated basal or squamous
             cell carcinoma of the skin at least 3 months prior to the start of study medication)

          -  Uncontrolled diabetes or Type 1 diabetes

          -  Unstable ischemic heart disease

          -  Serious active or recurrent infection, hepatic cirrhosis, or other medically unstable
             condition

          -  Systemic autoimmune diseases other than RA (such as systemic lupus erythematosus,
             scleroderma, inflammatory bowel disease, inflammatory myopathy)

          -  Positive for HIV, hepatitis B surface antigen, or hepatitis C antibody

          -  Pregnant or nursing females

          -  Inadequate hepatic, renal, or hematologic function

          -  Receipt of live vaccine within 5 weeks of start of study medication

          -  Concomitant administration of other biologic or non-biologic DMARDS, corticosteroids,
             or anti-CD20 antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Gannon, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Protalex, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Protalex Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protalex Investigational Site</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arthritis</keyword>
  <keyword>rheumatoid</keyword>
  <keyword>methotrexate</keyword>
  <keyword>leflunomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

